AASLD Briefs: Merck HCV Combo’s Four- and Six-Week Data Disappoint, Upside Seen For Gilead
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck’s proprietary two-drug combo, when used with Sovaldi, did not produce strong cure rates in short-term therapy, but an eight-week regimen in treatment-naïve cirrhotic patients may offer an advantage over Harvoni. Also, researchers estimate the total cost to treat HCV and recommend need-based prioritization of therapy.